BioPharma Dive November 11, 2024
Aucatzyl, developed by the U.K. biotech Autolus, may cause fewer side effects than Tecartus in people with a type of leukemia.
Dive Brief:
- The Food and Drug Administration on Friday approved a new cell therapy for a type of leukemia. Called Aucatzyl, the CAR-T was developed by U.K.-based Autolus Therapeutics to treat people with B-cell precursor acute lymphoblastic leukemia whose disease has progressed following treatment with chemotherapy and other medicines.
- Aucatzyl will compete with Gilead Sciences’ Tecartus, which won approval in the same condition in 2021. The Gilead cell therapy had sales of $305 million in the first nine months of 2024, but Autolus executives claim its drug could outperform Tecartus because it was designed to cause fewer side...
Today's Sponsors
Today's Sponsor